Management announced a transformational agreement to sell its entire branded U.S. commercial portfolio to Apotex for $100 million in cash plus inventory and milestone payments, subject to shareholder approval. The strategic shift transitions Cumberland from a commercial-stage entity to an innovation-driven organization focused on advancing its robust pipeline of product candidates. Performance in Q1 2026 was characterized by a 5% revenue increase in the core portfolio, excluding a prior-year one-time ...